newsfilter
← Latest News
Business Wire·

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Plans to file for approval with Breakthrough Therapy Designation in Saudi Arabia based on completed Phase 3 results CEL-SCI Corporation (NYSE:CVM) today reported financial results for the three months ended March 31,